RSV ComNet II: disease burden of Respiratory Syncytial Virus in primary care: Italy, United Kingdom and the Netherlands, 2020-2021

Duration: Nov 2020 - Dec 2021

This project is the follow-up to RSV ComNet I: Disease burden of RSV infections in young children (< 5 years) in primary care. A pilot study in Italy and the Netherlands in the winter of 2019/20

Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory tract infections in children. By the age of one year, 60-70% of children are infected with RSV and almost all children are infected by the age of two years. In western countries, mortality from RSV is rare. The rate of hospitalization in young children is estimated at 0.6 to 42.7 cases per 1000 children, with higher rates in younger children. Accurate estimates of the burden of RSV, including in primary care, are needed to assess the overall impact of RSV on society. This knowledge is critical for policy makers to make informed decisions about the introduction of new RSV interventions.

The aim of RSV ComNet is to measure the clinical and socio-economic burden of disease of RSV in young children (< 5 years) in primary care.

The burden of RSV in young children will be measured in the winter of 2020-2021 in the Netherlands and the United Kingdom. Both countries have chosen to use the infrastructure of the routine influenza surveillance network to recruit children for the RSV ComNet study. In the summer, data collection was extended because there was no RSV collection in the winter of 2020/2021 due to the COVID-19 pandemic.


More information:

Dit project wordt gesubsidieerd door
Sanofi Pasteur SA, France
University of Oxford, United Kingdom; Royal College of General Practitioners (RCGP), United Kingdom